Buckingham Capital Management Inc. raised its holdings in Celgene Co. (NASDAQ:CELG) by 14.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,045 shares of the biopharmaceutical company’s stock after acquiring an additional 2,455 shares during the quarter. Buckingham Capital Management Inc.’s holdings in Celgene were worth $2,923,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Palladium Partners LLC bought a new position in shares of Celgene during the third quarter worth $225,000. Commonwealth Equity Services Inc boosted its position in shares of Celgene by 2.3% during the third quarter. Commonwealth Equity Services Inc now owns 143,902 shares of the biopharmaceutical company’s stock worth $20,983,000 after purchasing an additional 3,186 shares in the last quarter. Commerce Bank boosted its position in shares of Celgene by 1.1% during the third quarter. Commerce Bank now owns 182,349 shares of the biopharmaceutical company’s stock worth $26,591,000 after purchasing an additional 2,050 shares in the last quarter. ACG Wealth boosted its position in shares of Celgene by 7.4% during the third quarter. ACG Wealth now owns 25,793 shares of the biopharmaceutical company’s stock worth $3,761,000 after purchasing an additional 1,784 shares in the last quarter. Finally, Abbrea Capital LLC boosted its position in shares of Celgene by 11.2% during the third quarter. Abbrea Capital LLC now owns 5,889 shares of the biopharmaceutical company’s stock worth $859,000 after purchasing an additional 595 shares in the last quarter. 79.85% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently commented on CELG shares. BMO Capital Markets boosted their price objective on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Celgene in a research report on Friday, October 20th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a research report on Monday, October 23rd. Cann reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and a consensus price target of $131.18.
Shares of Celgene Co. (NASDAQ CELG) opened at $104.82 on Wednesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market cap of $83,455.59, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 EPS. equities research analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/17/buckingham-capital-management-inc-acquires-2455-shares-of-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.